Compare AUPH & RLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUPH | RLX |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2014 | 2020 |
| Metric | AUPH | RLX |
|---|---|---|
| Price | $14.88 | $1.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $18.50 | $2.78 |
| AVG Volume (30 Days) | 819.4K | ★ 1.3M |
| Earning Date | 10-30-2026 | 11-20-2026 |
| Dividend Yield | N/A | ★ 7.53% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $16.65 | $62.88 |
| Revenue Next Year | $17.73 | $23.93 |
| P/E Ratio | ★ $19.89 | $28.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.52 | $1.45 |
| 52 Week High | $19.25 | $2.55 |
| Indicator | AUPH | RLX |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 27.35 |
| Support Level | $14.76 | N/A |
| Resistance Level | $15.15 | $2.08 |
| Average True Range (ATR) | 0.53 | 0.05 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 4.44 | 23.21 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.